Purpose: We compared the radioresponse of cervical carcinoma that was closely related to local disease control by the tumor regression rate (RR) during intracavitary radiotherapy (ICRT) and external beam radiotherapy (EBRT) on the presumption that ICRT has a stronger treatment impact than EBRT because of its specific dose distribution.
Materials And Methods: A total of 37 patients were treated by EBRT at 45.0 Gy over 5 weeks, followed by high-dose-rate ICRT at 6.0 Gy per weekly insertion at point A three to five times and by boost EBRT. RR was defined as the slope (day(-1)) of the tumor-volume shrinkage curve fit to an exponential regression equation. Assuming that the tumors were ellipsoid, the tumor volume was estimated using magnetic resonance (MR) images obtained before treatment, after 45.0 Gy of EBRT, and after the third ICRT insertion. RRs were compared based on the radiotherapy method.
Results: RR ranged between -0.008 to 0.093 day(-1) (median 0.021 day(-1)) during EBRT and -0.001 to 0.097 day(-1) (median 0.018 day(-1)) during ICRT, showing no significant difference or correlation between treatments.
Conclusion: Contrary to expectations, RR did not directly relate to the impact of physical treatment. RR could be related to biological factors, such as the amount of tumor clearance and changes in tumor consistency during treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11604-008-0268-1 | DOI Listing |
Discov Oncol
January 2025
Department of General Surgery, The Second Affiliated Hospital of the Air Force Medical University, Xi'an, 710038, China.
A common digestive system cancer with a dismal prognosis and a high death rate globally is breast cancer (BRCA). BRCA recurrence, metastasis, and medication resistance are all significantly impacted by cancer stem cells (CSCs). However, the relationship between CSCs and the tumor microenvironment in BRCA individuals remains unknown, and this information is critically needed.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Fever is a complication after colorectal endoscopic submucosal dissection (ESD). The objective of this study was to explore the incidence and risk factors of fever after colorectal ESD and establish a predictive nomogram model. This retrospective analysis encompassed patients with colorectal lesions who underwent ESD between June 2008 and December 2021 in our center.
View Article and Find Full Text PDFWorld J Urol
January 2025
Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
Purpose: To evaluate the association between the newly developed region of interest (ROI)-modified Mayo Adhesive Probability (MAP) score, in which stranding was re-evaluated by computed tomography (CT) number, for predicting operation time in robot-assisted partial nephrectomy (RAPN).
Methods: The study participants were 119 patients who underwent transperitoneal RAPN. With regard to stranding, ROIs were evaluated, and the mean CT numbers were assigned a score ranging from 0 to 3.
BMC Pulm Med
January 2025
Department of Geriatrics, Harrison International Peace Hospital, Intersection of Renmin Road, Hongqi Street, Taocheng District, Hengshui City, Hebei Province, 053000, China.
Objectives: To explore the factors related to the progression of chronic obstructive pulmonary disease (COPD).
Methods: 80 COPD patients treated between January 2020 and December 2022. The patients' pulmonary functions at their first hospital admission were categorized into four groups: Grade I, Grade II, Grade III and Grade IV.
J Immunother Cancer
January 2025
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!